Background Patients who have had a stroke with unknown time of onset have been previously
excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe …

… Song and Lyden are investigators at Cedars-Sinai for the Intravascular Cooling in the
Treatment of Stroke 2/3 Trial (ICTuS2/3). This study is part of the National Institutes of Health–…

A new type of metabolizable and efficient radiosensitizers for cancer radiotherapy is
presented by combining ultrasmall Au nanoclusters (NCs, <2 nm) with biocompatible coating …

This paper describes a 28-GHz CMOS direct conversion transceiver with packaged 2 × 4
patch antenna array for 5G communication. Beamforming antenna and reconfigurable …

Bi, a high atomic number element, has a high photoelectric absorption coefficient, and Se has
anticancer activity. Hence, their compound chalcogenide (Bi 2 Se 3 ) deserves a thorough …

The technology innovation for extending the RCAT structure to the sub-70nm DRAM is
presented. The new technology overcomes the problems induced by shrinkage of the RCAT …

Background and Purpose— The WEAVE trial (Wingspan Stent System Post Market Surveillance)
is a postmarket surveillance trial mandated by the Food and Drug Administration to …

Bacterial DNA and synthetic oligomers containing CpG dinucleotides activate the immune
system through Toll-like receptor (TLR) 9. Here, we compare the immunostimulatory activity of …

Vitamin D 3 upregulated protein 1 (VDUP1) is a stress-response gene that is upregulated by
1,25(OH) 2 D 3 in tumor cells. The in vivo roles of VDUP1 were investigated by producing …

Objective Most acute ischemic stroke (AIS) patients with unwitnessed symptom onset are
ineligible for intravenous thrombolysis due to timing alone. Lesion evolution on fluid‐…